+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Flexible, Rigid), By Application (Hospital, Clinic, Ambulatory Surgical Centers, Others), By End User (Pulmonologists, Thoracic Surgeons, Interventional Radiologists), By Procedure Type (Therapeutic Interventions, Interventional Diagnostics, Airway Stenting), By Technology (Video Bronchoscopes, Fiberoptic Bronchoscopes, Hybrid Systems), By Use Model (Reusable Bronchoscopes, Single-use Bronchoscopes), and Regional Forecast, 2026-2034
The global Therapeutic Bronchoscope market was valued at USD 1.78 billion in 2025 and is estimated at USD 1.89 billion in 2026. The market is projected to reach USD 3.08 billion by 2034, exhibiting a 6.3% CAGR during 2026–2034.
Therapeutic bronchoscopes are rigid or flexible endoscopic instruments designed to visualize and treat the tracheobronchial tree while providing a working channel for endotherapy devices. Therapeutic procedures include secretion removal, foreign-body extraction, tumor debulking, airway stent placement, laser or electrosurgical treatment, argon plasma coagulation, cryotherapy, balloon dilation, bronchial thermoplasty and selected interventions for emphysema or severe airway obstruction.
The market benefits from a large respiratory-disease treatment base. WHO reports that COPD caused 3.4 million deaths globally in 2023, while U.S. cancer statistics estimate 229,410 new lung and bronchus cancer cases in 2026. Interventional bronchoscopy is increasingly used to obtain tissue, manage central airway obstruction, remove foreign bodies and deliver minimally invasive therapies in patients for whom open surgery may carry greater morbidity.
Product innovation is focused on larger working channels, improved imaging, maneuverability and single-use sterility. FUJIFILM's EB-710XT therapeutic video bronchoscope provides a 3.2 mm instrument channel. Olympus BF-1TH190 combines HD imaging with 120-degree left/right insertion-tube rotation, while Ambu aScope 5 Broncho offers single-use models up to a 2.8 mm working channel and compatibility with active endotherapy tools. These design changes broaden the range of therapeutic procedures that can be performed through flexible bronchoscopy.
The study covers reusable and single-use therapeutic bronchoscopes and core endoscopic platforms intended for interventional procedures in the larynx, trachea and bronchial tree.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | Flexible; Rigid |
| By Application | Hospital; Clinic; Ambulatory Surgical Centers; Others |
| By End User | Pulmonologists; Thoracic Surgeons; Interventional Radiologists |
| By Procedure Type | Interventional Diagnostics; Therapeutic Interventions; Airway Stenting |
| By Technology | Video Bronchoscopes; Fiberoptic Bronchoscopes; Hybrid Systems |
| By Use Model | Reusable Bronchoscopes; Single-use Bronchoscopes |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | Olympus Corporation; KARL STORZ; Ambu A/S; Boston Scientific Corporation; Ethicon; FUJIFILM Holdings Corporation; Medtronic; HOYA / PENTAX Medical; Richard Wolf GmbH; Cook Medical; CONMED; Roper Technologies; Teleflex Incorporated; Broncus Medical; Hunan Vathin Medical Instrument; Shanghai Aohua Endoscopy; Shanghai Outai Medical |
COPD, lung cancer, severe asthma, airway stenosis and other pulmonary disorders create a broad need for bronchoscopic evaluation and intervention. WHO estimates 3.4 million COPD deaths globally in 2023, while lung cancer remains one of the most common and deadly cancers in the United States.
Therapeutic bronchoscopy can relieve central airway obstruction, remove foreign bodies, place stents and deliver energy or cryotherapy without thoracotomy. Reduced invasiveness supports use in frail patients and can shorten recovery relative to more invasive surgical approaches.
Larger instrument channels improve suction and permit passage of larger forceps, cryoprobes, stents and other therapeutic devices. FUJIFILM's EB-710XT uses a 3.2 mm channel and Ambu's 5.6/2.8 single-use model provides a 2.8 mm channel, illustrating the commercial importance of therapeutic channel design.
Reusable bronchoscopes require validated cleaning, high-level disinfection or sterilization, drying and storage. Single-use systems eliminate reprocessing and repair but shift economics toward per-procedure disposable cost.
Airway stenting, tumor ablation, laser therapy and management of bleeding or obstruction require specialist pulmonologists and support staff. Limited interventional pulmonology capacity constrains adoption in smaller hospitals and emerging healthcare systems.
Ambu positions aScope 5 Broncho for advanced diagnostic and therapeutic bronchoscopy and offers compatibility with biopsy forceps, cryoprobes and high-frequency instruments. This expands single-use products into procedures historically dominated by reusable scopes.
Olympus announced an exclusive global distribution agreement with Endocision in August 2026 for a portable single-use flexible cryocatheter platform intended to support diagnostic and therapeutic bronchoscopic procedures, with commercial launch expected in 2027.
FUJIFILM launched the EB-710US balloon-less EBUS bronchoscope in May 2026, targeting streamlined pulmonary staging and access. Although EBUS is primarily a diagnostic/interventional platform, improved visualization and instrument access reinforce the broader therapeutic bronchoscopy ecosystem.
Reusable therapeutic video bronchoscopes from Olympus, FUJIFILM and other major vendors continue to offer larger channels, HD imaging and compatibility with laser, APC, cryotherapy and other endotherapy tools.
China, India, Japan and South Korea are expanding tertiary respiratory centers and endoscopy infrastructure. Regional manufacturers also offer lower-cost bronchoscopes, improving access beyond premium global platforms.
Therapeutic bronchoscopy encompasses mechanical, thermal, cryogenic and implant-based interventions. Procedure choice depends on lesion location, airway urgency, bleeding risk, operator expertise and available equipment.
| Procedure / Intervention | Role of Bronchoscope | Commercial Relevance |
|---|---|---|
| Tumor debulking | Provides visualization, suction and a channel for mechanical, laser, electrocautery, APC or cryotherapy devices. | High-value interventional use in central airway obstruction. |
| Airway stenting | Rigid or large-channel flexible bronchoscopy supports deployment and repositioning of airway stents. | Specialist procedure with strong accessory-device linkage. |
| Foreign-body removal | Working channel accepts forceps, baskets and retrieval devices. | Common therapeutic function across adult and pediatric care. |
| Bleeding management | Enables suction, localization and delivery of coagulation or hemostatic therapy. | Important emergency and post-biopsy application. |
| Bronchial thermoplasty | Bronchoscope delivers a radiofrequency catheter to airways in selected severe asthma patients. | Specialized procedure requiring trained centers. |
| Endobronchial valve / lung-volume procedures | Bronchoscope delivers one-way valves or related emphysema interventions. | Growing advanced COPD treatment segment. |
Flexible bronchoscopes dominate the market, while rigid bronchoscopes retain an indispensable role in complex central-airway interventions.
Flexible bronchoscopes offer maneuverability through segmental bronchi and are used for biopsy, suction, foreign-body retrieval, thermal therapy and many routine interventional procedures. Video technology and large working channels have expanded their therapeutic scope.
Rigid bronchoscopy provides a large lumen for ventilation, suction, stent deployment and management of severe central-airway obstruction. It remains important when airway control and large instruments are required.
Hospitals are the largest application segment because complex airway procedures require advanced infrastructure and multidisciplinary support.
Tertiary hospitals concentrate interventional pulmonology, thoracic surgery, anesthesia and intensive-care services required for complex airway intervention. They also manage complications such as bleeding and pneumothorax.
Pulmonology clinics perform selected lower-complexity procedures and follow-up bronchoscopy, particularly where sedation and emergency support are available.
ASCs can support selected bronchoscopic procedures as minimally invasive care shifts away from inpatient hospitalization, subject to procedure complexity and reimbursement.
Academic research centers, specialty cancer facilities and advanced ambulatory endoscopy centers contribute additional demand.
Pulmonologists are the primary users, while thoracic surgeons and interventional radiologists participate in selected complex or image-guided airway procedures.
Interventional pulmonologists perform airway evaluation, biopsy, debulking, stenting, foreign-body removal and other bronchoscopic treatments. Their procedural volume is the central driver of device utilization.
Thoracic surgeons use rigid and flexible bronchoscopy for airway assessment, stenting, operative planning and treatment of selected tracheobronchial lesions.
Image-guided specialists increasingly collaborate in peripheral lung biopsy, ablation and complex thoracic interventions that integrate bronchoscopic access and advanced navigation.
Therapeutic Interventions represent the most dynamic segment, while interventional diagnostics remain essential to lesion localization and treatment planning.
Tumor debulking, laser/APC, cryotherapy, dilation, foreign-body removal and other direct treatments are expanding as minimally invasive pulmonary care advances.
Biopsy, EBUS, sampling and navigation establish diagnosis and staging and frequently precede therapeutic decisions. Advanced bronchoscopes increasingly support both diagnostic and therapeutic steps in one session.
Stenting requires precise visualization, adequate working space and often rigid bronchoscopy or large-channel flexible systems. It is critical in malignant and benign central-airway obstruction.
Video Bronchoscopes lead because HD digital imaging, image enhancement and documentation provide greater procedural visibility than traditional fiberoptic-only systems.
Current systems integrate digital sensors, HD processors and electronic image enhancement. Olympus, FUJIFILM and Ambu all compete with digital platforms designed for therapeutic procedures.
Fiberoptic scopes retain roles in selected facilities, emergency backup and cost-sensitive markets but continue to lose share to digital video systems.
Hybrid and multimodal systems combine bronchoscopy with EBUS, navigation, fluoroscopy, robotic guidance or other imaging to improve lesion access and intervention planning.
Reusable bronchoscopes retain the largest installed value base, while single-use bronchoscopes are the strongest disruption because they eliminate reprocessing and repair.
Reusable systems provide high-end imaging, broad scope families and strong integration with endoscopy towers. Their economics improve with high procedure volumes but depend on reprocessing and maintenance.
Single-use systems arrive sterile, avoid repair downtime and eliminate inter-patient reprocessing. Ambu's aScope 5 family is specifically positioned for demanding diagnostic and therapeutic bronchoscopy.
North America is the largest regional market. The United States combines high lung-cancer burden, advanced interventional pulmonology, strong hospital capital budgets, rapid adoption of single-use endoscopy and active FDA clearance of new bronchoscope systems. Academic centers also lead clinical adoption of robotic and navigational bronchoscopy.
Europe is a mature market with strong endoscopy adoption, reusable-scope infrastructure and increasing single-use penetration. Germany, the United Kingdom and France are major procedure markets, while MDR compliance and hospital reprocessing standards shape procurement.
Asia-Pacific is the fastest-growing major region. China, Japan, India and South Korea are expanding pulmonary medicine, cancer diagnosis and tertiary endoscopy. Regional manufacturers such as Vathin and Aohua compete on price and domestic service.
Brazil, Mexico and Argentina lead regional demand. Adoption is concentrated in major urban hospitals, and advanced interventional procedures depend on trained specialists and access to energy, stent and navigation accessories.
GCC countries support high-end interventional pulmonology through advanced tertiary hospitals, while much of Africa remains limited by equipment and specialist availability. Growth follows respiratory-center development and cancer-care investment.
Bronchoscopes are Class II devices in the United States and are subject to recognized endoscope safety, performance and reprocessing requirements.
| Regulatory / Safety Element | Current Context | Market Effect |
|---|---|---|
| FDA Class II classification | Flexible and rigid bronchoscopes fall under 21 CFR 874.4680, product code EOQ, with 510(k) review. | Creates a defined premarket pathway and consensus-standard expectations. |
| Olympus K250862 | FDA cleared multiple Olympus bronchovideoscopes, including BF-1TH1100, in June 2025. | Confirms continuing renewal of reusable therapeutic platforms. |
| Laser / APC / HF cautery labeling | Olympus issued a global corrective action in 2025 to clarify safe bronchoscope use with laser, argon plasma coagulation and high-frequency therapy because of endobronchial combustion risk. | Raises training and oxygen-management requirements during energy-based therapy. |
| Single-use recall activity | FDA posted a 2025 recall affecting Ambu aScope 5 Broncho HD sampler sets. | Demonstrates that single-use products also require robust quality surveillance. |
| Reusable reprocessing | Reusable scopes require validated cleaning, disinfection or sterilization and drying between patients. | Adds labor, capital and infection-control cost to reusable economics. |
Competition is led by large endoscopy companies with established video platforms, while single-use specialists and regional Asian manufacturers add new pressure around infection control and cost.
Olympus maintains a broad therapeutic bronchoscopy franchise. BF-1TH190 provides HD imaging and 120-degree rotation, while the newer BF-1TH1100 is covered by a 2025 FDA clearance. Olympus also expanded its respiratory portfolio through the 2026 Endocision cryobiopsy distribution agreement.
KARL STORZ has deep expertise in rigid bronchoscopy, airway surgery and endoscopic instruments, supporting complex central-airway interventions and operating-room workflows.
aScope 5 Broncho provides sterile single-use bronchoscopy in four sizes, including HD 5.6/2.8 and 5.0/2.2 models, and is compatible with common therapeutic endotherapy instruments.
FUJIFILM's EB-710XT therapeutic bronchoscope provides a 3.2 mm working channel, while the 2026 EB-710US launch expands the company's pulmonary EBUS portfolio.
These companies participate through airway stents, ablation, valves, retrieval, biopsy and related interventional pulmonology devices that reinforce bronchoscope utilization.
Regional manufacturers expand access through lower-cost reusable and single-use systems, especially in China and emerging markets.
13 August 2026: Olympus announced an exclusive global distribution agreement with Endocision for a portable single-use flexible cryocatheter system designed to support diagnostic and therapeutic bronchoscopic procedures, with commercial launch expected in 2027.
18 May 2026: FUJIFILM Healthcare Americas launched the EB-710US next-generation balloon-less EBUS bronchoscope for pulmonary care, expanding its interventional bronchoscopy platform.
3 November 2025: FDA published Olympus' global medical-device corrective action updating instructions for bronchoscopes used with laser therapy, argon plasma coagulation and high-frequency cauterization following reports of endobronchial combustion.
23 June 2025: FDA cleared Olympus K250862 covering EVIS EXERA III and newer bronchovideoscope models including BF-1TH1100, maintaining active U.S. product renewal in flexible bronchoscopy.
The global Therapeutic Bronchoscope market is projected to grow from USD 1.89 billion in 2026 to USD 3.08 billion by 2034, at a 6.3% CAGR. Growth will be driven by minimally invasive airway therapy, single-use adoption, advanced imaging, cryotherapy and expansion of interventional pulmonology in Asia-Pacific.
| Forecast Variable | Current Direction | Expected Effect Through 2034 |
|---|---|---|
| Respiratory disease burden | COPD and lung cancer remain major causes of morbidity and mortality. | Sustains intervention demand. |
| Flexible bronchoscopy | Large-channel video platforms continue to expand therapeutic capability. | Supports leading product segment. |
| Single-use systems | Advanced disposable bronchoscopes are moving into bronchoscopy suites. | Raises recurring device revenue. |
| Interventional tool ecosystem | Cryotherapy, stents, valves and energy tools continue to expand. | Broadens procedure range. |
| Asia-Pacific capacity | Specialist training and hospital endoscopy infrastructure are growing. | Creates strongest regional growth. |
The study supports interventional pulmonology strategy, bronchoscope procurement, endoscopy portfolio planning, hospital workflow design and competitive benchmarking.
Market sizing combines bottom-up supplier, product, pricing and utilization analysis with top-down demand validation. Quantitative inputs include treated-patient or procedure volumes, product mix, dose or replacement cycles, end-user structure, regional access and average selling values.
Primary research validates treatment or procedural workflows, purchasing criteria, adoption barriers and competitive positioning. Secondary research prioritizes regulators, public-health agencies, professional bodies, peer-reviewed evidence and official manufacturer information. Forecast assumptions are cross-checked against utilization, regulatory activity, technology development and regional healthcare capacity.
Forecasts incorporate therapeutic bronchoscopy procedure growth, flexible-versus-rigid use, reusable-versus-single-use mix, installed endoscopy systems, replacement cycles, working-channel and video-technology premiumization, hospital capital expenditure and interventional pulmonology capacity. North America remains the largest value market, while Asia-Pacific receives the strongest new-installation and procedure-growth assumptions.
The market was valued at USD 1.78 billion in 2025 and is estimated at USD 1.89 billion in 2026. It is projected to reach USD 3.08 billion by 2034, representing a 6.3% CAGR.
Flexible bronchoscopes are the leading type because of maneuverability, patient tolerance and compatibility with a wide range of diagnostic and therapeutic tools.
Hospitals are the largest application setting because complex bronchoscopy requires specialist teams, anesthesia support and management of procedural complications.
Video Bronchoscopes are the leading technology because HD digital imaging improves visualization, documentation and procedural precision.
North America is the largest regional market, while Asia-Pacific is expected to record the fastest growth.
They can support tumor debulking, airway stenting, foreign-body removal, suction, laser or electrosurgical therapy, argon plasma coagulation, cryotherapy, dilation and selected emphysema interventions.
The report profiles Olympus, KARL STORZ, Ambu, Boston Scientific, FUJIFILM, Medtronic, PENTAX Medical/HOYA, Richard Wolf, Cook Medical, CONMED, Teleflex, Broncus Medical, Vathin, Aohua and other manufacturers.
The public overview uses 2025 as the base year, 2026 as the estimated year and 2026–2034 as the forecast period.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
